Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8083-8092

  Cryan, Jane B ^a   Haidar, Sam ^b   Ramkissoon, Lori A ^b   Bi, Wenya Linda ^a   Knoff, David S ^b   Schultz, Nikolaus ^d   Abedalthagafi, Malak ^a   Brown, Loreal ^b   Wen, Patrick Y ^b   Reardon, David A ^b   Dunn, Ian F ^a   Folkerth, Rebecca D ^a   Santagata, Sandro ^a,c   Lindeman, Neal I ^a   Ligon, Azra H ^a   Beroukhim, Rameen ^b   Hornick, Jason L ^a   Alexander, Brian M ^b   Ligon, Keith L ^a,b,c   Ramkissoon, Shakti H ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Astrocytoma; IDH; Oligoastrocytoma; Oligodendroglioma; Sequencing

Indexed keywords

ATRX PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PEPTIDES AND PROTEINS; PROTEIN P53; UNCLASSIFIED DRUG; ATRX PROTEIN, HUMAN; DNA HELICASE; EGFR PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; ASTROCYTOMA; ATRX GENE; CANCER STAGING; CONTROLLED STUDY; EGFR GENE; EXOME; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; MAJOR CLINICAL STUDY; MIXED TUMOR; OLIGODENDROGLIOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TP53 GENE; TUMOR CLASSIFICATION; BRAIN TUMOR; CELL LINEAGE; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOHISTOCHEMISTRY; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY;

ASTROCYTOMA; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL LINEAGE; DIAGNOSIS, DIFFERENTIAL; DNA HELICASES; DNA MUTATIONAL ANALYSIS; EXOME; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MUTATION; NUCLEAR PROTEINS; OLIGODENDROGLIOMA; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907998639     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2342     Document Type: Article

References (26)

1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013; 15 Suppl 2:ii1-56.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352(10):987-996.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-466.
4. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA and Huse JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012; 3(10):1194-1203.
5. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J, Dong Z, Siegel P, Albrecht S, Croul S, Jones DT, Kool M, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta neuropathologica. 2012; 124(5):615-625.
6. Sanai N, Chang S and Berger MS. Low-grade gliomas in adults. Journal of neurosurgery. 2011; 115(5):948-965.
7. Grier JT and Batchelor T. Low-grade gliomas in adults. Oncologist. 2006; 11(6):681-693.
8. Olson JD, Riedel E and DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000; 54(7):1442-1448.
9. Shafqat S, Hedley-Whyte ET and Henson JW. Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurology. 1999; 52(4):867-869.
10. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
11. Castillo MS, Davis FG, Surawicz T, Bruner JM, Bigner S, Coons S and Bigner DD. Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuroepidemiology. 2004; 23(1-2):85-93.
12. Aldape K, Simmons ML, Davis RL, Miike R, Wiencke J, Barger G, Lee M, Chen P and Wrensch M. Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer. 2000; 88(10):2342-2349.
13. Reifenberger G and Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. Journal of neuropathology and experimental neurology. 2003; 62(2):111-126.
14. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-773.
15. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica. 2009; 118(4):469-474.
16. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL and Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009; 324(5924):261-265.
17. Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stutz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013; 45(8):927-932.
18. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, Corcoran A, Jones DT, Sturm D, Johann P, Tomita T, Goldman S, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014; 46(5):462-466.
19. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schuler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lutolf UM, Kleihues P and Ohgaki H. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta neuropathologica. 2004; 108(1):49-56.
20. Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH and Stiles CD. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 2011; 19(3):359-371.
21. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M and Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta neuropathologica. 2013; 126(3):443-451.
22. Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE, Croul SE, Santi MR, Cheng J, Zhou S, Sullivan LM, Martinez-Lage M, Judkins AR and Perry A. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2013; 26(11):1425-1432.
23. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, et al. Profiling critical cancer gene mutations in clinical tumor samples. PloS one. 2009; 4(11):e7887.
24. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB and Garraway LA. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer discovery. 2012; 2(1):82-93.
25. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2(5):401-404.
26. Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD and Rowitch DH. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. Journal of neuropathology and experimental neurology. 2004; 63(5):499-509.